Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.71%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.36, delivering a surprise of 25%.Over the last four quarters, the company has ...